Home
News
Screeners
Insights
Goldline Pharmaceutical
33.
00
+0.65
(+2.01%)
Market Cap
₹31.72 Cr
PE Ratio
-
Industry
-
Buy
Sell
Company Performance:
1D
+2.01%
1M
-19.45%
6M
-41.87%
1Y
-41.87%
5Y
-41.87%
View Company Insights
Latest news about Goldline Pharmaceutical
Goldline Pharmaceutical promoter raises stake to 29.27% with open market buy
Sep 02, 2026
Promoter Amol Laxmikant Mujumdar acquired 60,000 shares via open market. Stake increased by 0.62% to reach 29.27% of paid-up capital. Total issued share capital remains unchanged at 9.6 million shares. No encumbrances or pledges reported on the promoter's holdings.
Goldline Pharmaceutical promoter acquires 18,000 shares via open market
Sep 02, 2026
Goldline Pharma shareholders approve director loans, related-party deals
Aug 31, 2026
Goldline Pharma net profit jumps 45% to ₹411.71 lakhs in FY26
Aug 29, 2026
Goldline Pharmaceutical promoter Swapan Khandelwal acquires 78,000 shares
Aug 29, 2026
More news about Goldline Pharmaceutical
07
Aug 26
Goldline Pharmaceutical schedules 22nd AGM for August 29, 2026
Goldline Pharmaceutical Limited will hold its 22nd AGM on August 29, 2026, in Nagpur. Remote e-voting is available from August 25 to August 28, 2026, via Bigshare Services. The record date for voting eligibility is August 22, 2026, and the share transfer books will be closed from August 23 to August 29, 2026.
14
Jul 26
Goldline Pharmaceutical appoints secretarial auditor for FY26
Goldline Pharmaceutical Ltd has appointed M/s. Avinash Gandhewar & Associates as its Secretarial Auditor for FY2025-26. The Board approved the appointment on July 14, 2026, effective from April 1, 2025, to March 31, 2026. The firm specializes in Company Law, Securities Laws, and Mergers and Acquisitions.
24
Jun 26
Goldline Pharmaceutical promoter raises stake to 29.27%
Goldline Pharmaceutical Limited disclosed that promoter Swapan Khandelwal acquired 60,000 equity shares on June 22, 2026, increasing his holding to 29.27%. The transaction was executed through the open market and disclosed to BSE under SEBI SAST regulations.
09
Jun 26
Goldline Pharmaceutical FY26 net profit rises 45% to ₹411.71 lakh
Goldline Pharmaceutical Limited reported a 45.2% rise in net profit to ₹411.71 lakh for FY26, with revenue increasing 11.2% to ₹3,119.76 lakh. The Board approved the audited results on June 09, 2026, and appointed M/s. Kunal Dutt & Associates as Internal Auditor.
02
Jun 26
Goldline Pharmaceutical board to consider FY26 results on June 9
Goldline Pharmaceutical Limited will hold a board meeting on June 09, 2026, to consider standalone audited financial results for the half-year and year ended March 31, 2026. The meeting will take place at the company's registered office in Nagpur.
Goldline Pharmaceutical
33.
00
+
0.
65
(+
2.
01
%)
1 Year Returns:
-41.87%
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar